This message was sent to ##Email##
|
|
|
|
|
| |
| HEALTH CARE NEWS AND UPDATES |
Kognito
Meet Linda. She is a five-year cancer survivor and is on our website to give helpful advice to women diagnosed with triple-negative breast cancer. About 10 percent of women with breast cancer have the triple-negative type. African-American women are more likely to have it than women from other racial and ethnic groups.
This type of cancer tends to grow quickly and is harder to treat compared with other types of breast cancer. But Linda is here to help. She guides women through their treatment options as well as what to expect from the treatments they will receive. More importantly, Linda gives women hope that they will get through the experience. If you or someone you love is dealing with triple-negative breast cancer, download the app today.
READ MORE
Labiotech
Artificial intelligence (AI) and machine learning are (not that) new technologies that have been recently boosted thanks to hardware improvements. Through algorithms, they can learn, predict and advise based on vast amounts of data. One of the areas where AI is expected to have a major impact is health care, where it can be used to interpret the data from the massive databases gathered over the years by companies, health care providers and payers. In particular, the treatment of cancer could greatly benefit from the arrival of AI technology.
READ MORE
 |
|
Our ihcDirect® method yields a revolutionary technology that opens a spectrum of new clinical applications including intraoperative surgery. Using the Novodiax PolyHRP technology, Intraoperative IHC tests can now be completed in just 10 minutes using fresh frozen tissues.
For more details, see our
 ihcDirect® product list.
|
|
ScienceDaily
Through x-ray crystallography and kinase-inhibitor specificity profiling, researchers reveal that curcumin, a natural occurring chemical compound found in the spice turmeric, binds to the kinase enzyme dual-specificity tyrosine-regulated kinase 2 (DYRK2) at the atomic level. This previously unreported biochemical interaction of curcumin leads to inhibition of DYRK2 that impairs cell proliferation and reduces cancer burden.
READ MORE
The Daily Iowan
The FDA has approved CAR T-cell therapy, a treatment for some types of cancer at the University of Iowa Hospitals & Clinics.
The UI Holden Comprehensive Cancer Center is the only hospital in Iowa and one of the few institutions nationwide that is certified to deliver CAR T-cell therapy, which genetically alters patients’ T-cells in their immune systems to target and then fight off cancer cells.
READ MORE
|
Promoted by
|
|
|
|
 |
Medical Xpress
Increasingly, doctors are treating lung cancer based on the genetic rearrangements driving the disease. For example, cancers that are driven by changes in the genes ALK, EGFR and ROS1 can now all be paired with drugs that target these specific changes. However, these cancers are not only dangerous in the lung where they appear, but can become especially dangerous if they are able to metastasize to the brain — a common cause of death from lung cancer. And some targeted treatments work better than others against cancer that has spread to the brain.
READ MORE
STAT
Preventive care experts have been divided for years on how to best counsel women on when to get breast cancer screenings. But a new study suggests that women might benefit from individualized approaches to mammograms rather than from universal guidelines.
READ MORE
 |
|
Donate now to help Doctors Without Borders bring emergency medical care where it is needed most. Doctors Without Borders USA relies on unrestricted donations from private donors so when an emergency strikes we assess the needs and can act fast.
Donate today.
|
|
R&D Magazine
Mayo Clinic researchers are using precision genomics to search for undiscovered, inheritable genetic mutations that cause accelerated aging. In a study recently published in Mayo Clinic Proceedings, researchers conducted a study assessing 17 patients with short telomere syndromes -- rare conditions that result in premature DNA and cellular deterioration. The ability to pinpoint the genetic abnormalities associated with short telomere syndromes is key to finding better ways to screen, diagnose and treat patients.
READ MORE
Medical Xpress
Researchers from the University of California San Diego have identified an unexpected mechanism that could help determine whether a cancer patient will respond to immunotherapy.
Ideally, the immune system identifies tumors as threatening elements and deploys immune cells (T cells) to find and kill them. However, tumor cells have evolved to employ a protein called PD-L1 to blind T cells from carrying out their functions and evade immune defenses. PD-L1 protects tumor cells by activating a "molecular brake" known as PD-1 to stop T cells.
READ MORE
Smithsonian
Chemotherapy comes with some nasty side effects, including weakness, nausea, hair loss and “chemo brain.” But one of the most frustrating is dysgeusia, a side effect that causes food to taste bland, bitter, metallic or simply off, meaning patients can’t lean on their favorite comfort foods when things get rough. But Elizabeth Zahradnicek-Haas at NPR reports that one brewery in the Czech Republic has created a beer with breast cancer patients undergoing chemo in mind, a non-alcoholic tipple full of vitamins and minerals with a flavor profile designed to overcome dysgeusia.
READ MORE
HPC Wire
Health care is evolving rapidly. Nothing demonstrates this fact more clearly than genomics. The original Human Genome Project took 13 years to complete and cost $2.7 billion. Today, according to IDC, whole-genome sequencing costs less than $1,000 and can be completed in as little as 27 hours.
READ MORE
| ACS CANCER PROGRAMS UPDATES |
ACS
2018 Cancer Programs Annual Conference: Learn. Interact. Transform.
Sept. 5-7
Chicago
Don't miss the opportunity to be a part of this exciting conference targeted to health care professionals committed to providing comprehensive, multidisciplinary, high-quality, patient-centered care by sharing your knowledge and expertise with your peers and colleagues and respond to the call for posters/resources. Complete submissions are due by Friday, July 20.
More than one submission by an individual is allowed. We ask that there only be one author or potential presenter for each poster or resource/template.
Plan to attend the conference that brings together program leadership, cancer committee members, navigators, nurses, physicians (cancer liaison physicians), and registrars. Visit the Cancer Programs Conference website for more information. Register today!
READ MORE
ACS
Please join the American Joint Committee on Cancer for a free webinar on Head and Neck Staging for the 8th Edition Cancer Staging Manual. The webinar will be held at 1 p.m. CDT July 25. Donna Gress, RHIT, CTR, will facilitate the webinar. In this webinar you will learn how to:
- Explain cervical nodes and unknown primary tumors
- Examine importance of EBV and HPV-mediated (p16+)
- Analyze extranodal extension (ENE)
Register here.
ACS
If your cancer program is considering accreditation, you have a survey around the corner or you have staff new to CoC/NAPBC accreditation, you should attend the pre-conference sessions at the 2018 Cancer Programs Annual Conference on Wednesday, Sept.5.
This is the ideal day for newly accredited centers, or those seeking more information on what being accredited involves to attend.
Colette Salm-Schmid, MD, FACS, will kick off the day with a presentation on the "Value of Accreditation." David P. Winchester, MD, FACS, Medical Director, Cancer Programs, will then present a brief overview of the common threads between the CoC and NAPBC standards. The group will then break into concurrent sessions on CoC Accreditation 101 or NAPBC Pursuing Excellence. You can select which program would be more beneficial for you. At the end of the day, participants will reconvene for a general session on "Putting Your Best Foot Forward at Survey." Here a CoC and NAPBC surveyor, as well as a network surveyor, will offer advice and tips on how to shine during survey.
Don't to miss the Cancer Programs Annual Conference! This is the only time these workshops will be offered in 2018! Register today to ensure your spot and secure our early-bird pricing. For further information, visit the Cancer Programs Annual Conference website.
READ MORE
ACS
The American College of Surgeons (ACS) 2018 Cancer Programs Annual Conference: Learn. Interact. Transform provides cutting-edge solutions to help you deliver high-quality, patient-centered, multidisciplinary care to patients with cancer. Through a combination of plenaries, breakout sessions and networking opportunities you will leave this conference reinvigorated and ready to overcome the challenges facing you as a cancer care provider.
Conference Highlights:
- CoC Accreditation 101 and Pursing Excellence though NAPBC Accreditation Pre-Conference Workshops on Wednesday, Sept 5
- Value of Navigation and Survivorship
- Mock Tumor Boards
- Components of a Quality Study
- Poster Sessions (we are still accepting applications – submit poster submission today)
- Exhibits
Detailed information, as well as conference agenda, can be found on the Cancer Programs Annual Conference website.
Register now to take advantage of the early-bird registration fee and SAVE.
READ MORE
American College of Surgeons - NAPRC
The National Accreditation Program for Rectal Cancer (NAPRC) is now accepting applications. The NAPRC was developed to ensure that rectal cancer patients receive appropriate care following a multidisciplinary approach. Programs will be evaluated on the standards and metrics outlined in The National Accreditation Program for Rectal Cancer Standards Manual 2017 (revised October 2017).
READ MORE
ACS
The AJCC Cancer Staging Manual is the gold standard to help the cancer patient management team determine the correct stage for patients, allowing for the most appropriate care plan.
The AJCC Cancer Staging Manual is used by physicians and health care professionals throughout the world to facilitate the uniform description and reporting of neo-plastic diseases. Proper classification and staging of cancer is essential for the physician to assign proper treatment, evaluate results of management and clinical trials and to serve as the standard for local, regional and international reporting on cancer incidence and outcome.
This corrected third printing includes the following features:
- Revised breast cancer staging system
- Revised histology codes in each chapter
- Corrected errata posted on www.cancerstaging.org through Feb. 2, 2018
Special 25 percent discount expires Sept. 30!
Order your copy today.
ACS
The National Cancer Database (NCDB) is pleased to announce that the Participant User File (PUF) application will open July 9 through Aug. 6. The NCDB will accept applications for site-specific files, which include cases diagnosed between 2004 and 2015. The 2016 PUF, which will include 2004-2016 diagnosis years, will be available for request during the next application period, January 2019.
The NCDB PUF is a Health Insurance Portability and Accountability Act (HIPAA) compliant data file containing cases submitted to the Commission on Cancer's (CoC) NCDB and complies with the terms of the Business Associate Agreement between the American College of Surgeons and cancer programs accredited by the CoC; i.e., no patients or facilities can be identified. The PUF is designed to provide investigators at CoC-accredited cancer programs with a data resource they can use to review and advance the quality of care delivered to cancer patients through analyses of cases reported to the NCDB.
For more information, review the PUF Website.
Questions regarding the NCDB PUFs or the RFA process for a PUF may be directed to NCDB technical staff at NCDB_PUF@facs.org.
| IMPORTANT DATES AND DEADLINES |
| Date |
Event |
Location |
| July 21-24 |
ACS Quality and Safety Conference
|
Orlando, FL
|
| Sept. 5-7 |
2018 Cancer Programs Conference
|
Chicago, IL
|
| Oct. 21-25 |
ACS Clinical Congress
|
Boston, MA
|
|
Missed last week's issue? See which articles your colleagues read most.
|
Don't be left behind. Click here to see what else you missed.
|
|
|
|
The Brief
Connect with AJCC
Connect with CoC
Connect with NAPBC
Recent Issues | Subscribe | Unsubscribe | Advertise | Web Version
Colby Horton, Vice President of Publishing, 469-420-2601 | Download media kit
Ashley Harrington, Senior Content Editor, 469-420-2642 | Contribute news
Disclaimer: The Brief is a digest of news selected for the Commission on Cancer (CoC) and the National Accreditation Program for Breast Centers (NAPBC), both quality programs of the American College of Surgeons, from thousands of sources by the editors of MultiBriefs, an independent organization that also manages and sells advertising. The Cancer Programs do not endorse any of the advertised products and services. Opinions expressed in the articles are those of the authors and not of the American College of Surgeons, and the Cancer Programs.
American College of Surgeons
633 N Saint Clair Street | Chicago, IL, 60611-3211 | 800-621-4111 | Contact Us
Learn how to add us to your safe sender list so our emails get to your inbox. |
|
| |
|
|
7701 Las Colinas Ridge, Ste. 800, Irving, TX 75063
|
®: Cancer Data at Your Fingertips